Elucid Bioimaging Inc. raised $56,235,000 (Boston, MA)

LIVE PUBLIC DATA Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) · Last refreshed: Wed, 04 Nov 2026 01:28:40 GMT

Elucid Bioimaging Inc. plus every comparable record, with all columns and source links, as one CSV.

Not investment advice and not an offer or solicitation to buy or sell any security.

68 / 100 vendor spend propensity

Estimated post-raise budget for CPA / Tax / Audit services: $1,124,700 (heuristic)

  • Operating company: new capital typically funds hiring, facilities and vendors.
  • Raised $56,235,000 so far: a large raise.
  • Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
FieldValue
IndustryBiotechnology (Healthcare & Life Sciences)
Operating companyYes
Exemption506(b)
Amount sold$56,235,000
Total offering$79,999,999
Investors so far20
First sale2025-10-10
Filed2026-10-27 (amendment)
EntityCorporation

Executives and related persons (from the filing)

  • Blake Richards: Executive Officer
  • Scott Huennekens: Director
  • Michael Lesh: Director
  • Richard Kuntz: Director
  • Evan Melrose: Director
  • Shamiram Feinglass: Director
  • Kelly Huang: Executive Officer, Director
  • Rajesh Panda: Director

View the filing on SEC EDGAR

Markdown version

Elucid Bioimaging Inc. vs. top 3 peers

OrganizationLocationCapital raisedRecord date
Elucid Bioimaging Inc.Boston$56,235,0002026-10-27
BigHat Biosciences, Inc.San Mateo$75,141,0862026-10-26
Vesalius Longevity Labs Inc.Vancouver$30,112,5002026-11-03
XRHealth, Inc.Needham$16,253,0292026-10-23

Related records

Newly funded companies in Massachusetts (SEC Form D) Newly funded Healthcare & Life Sciences companies (SEC Form D)

Get new raises like this every morning

FormDPulse emails you newly funded companies that match your ideal customer profile.

See plans

Often used together

Or get the Advisor Prospecting Bundle for $14.99 one-time: Full CSV unlock of newly funded companies plus a grant readiness pack.